Monthly Oncology Tumor Boards: Advances in the Management of Gastrointestinal Stromal Tumors (GIST) and Other Soft Tissue Sarcomas

September 21, 2021

The diagnosis and treatment of soft tissue sarcomas (STS) has been updated within recent years. Morphological tissue diagnosis in conjunction with ancillary molecular genetic testing is considered the gold standard for diagnosis. Treatment modalities have also expanded to include novel systemic therapies and advanced radiotherapy and ablative approaches. Continued education for oncology care providers is necessary to convey updates in the management of STS and improve patient outcomes.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Review the newer molecular genetic testing techniques used for the diagnosis of GIST and other soft tissue sarcomas (STS).
  • Summarize new systemic therapy options available for the treatment of different sarcomas.
  • Discuss the multidisciplinary care considerations for the management of STS.
Additional information
Supporters: 

This activity is supported by educational grants from: 

  • AstraZeneca
  • Blueprint Medicines
  • Epizyme Inc.
  • GlaxoSmithKline
  • Lilly
  • Novartis
  • Puma Biotechnology
  • Sanofi Genzyme

This activity is supported by independent medical education grants from:

  • Bristol Myers Squibb
  • Illumina, Inc
  • Pharmacyclics LLC, an AbbVie company and Janssen Biotech, Inc. 

This activity is supported by an independent educational grant from Astellas.

This educational activity is supported by a medical education grant from Exelixis, Inc.
 

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
07/21/2021
Course expires: 
11/30/2021
Event starts: 
09/21/2021 - 3:30pm EDT
Event ends: 
09/21/2021 - 4:30pm EDT
Cost:
$0.00
Part of: 
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care (June 2021 - May 2022)
Add to calendar: 

Margaret von Mehren, MD
Fox Chase Cancer Center

Jeffrey M. Farma, MD
Fox Chase Cancer Center

Eric D. Tetzlaff, MHS, PA-C
Fox Chase Cancer Center

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Margaret von Mehren, MD
Blueprint Medicines: Grant/Research Support
Deciphera Pharmaceuticals, Inc.: Grant/Research Support; Honoraria; Scientific Advisor
Eli Lilly and Company: Grant/Research Support 
Exelixis Inc.: Scientific Advisor
Genmab A/S: Grant/Research Support 
GlaxoSmithKline: Scientific Advisor 
Gradalis, Inc.: Grant/Research Support 
Novartis Pharmaceuticals Corporation: Grant/Research Support
Royalties on Sale of Cell Line Developed: Royalty Income 
Salarius Pharmaceuticals, Inc.: Grant/Research Support
Spring Works Therapeutics: Grant/Research Support 
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support 

Jeffrey M. Farma, MD
Delcath Systems, Inc.: Other Financial Benefit

Eric D. Tetzlaff, MHS, PA-C
Blueprint Medicines: Consulting Fee; Product/Speakers Bureau

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-21-042-L01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00047576; Approval #: 210002946

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

This webinar was presented live one time only on Tuesday, September 21, 2021, from 3:30 – 4:30 PM EDT (UTC -4).
View the recorded activity here

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing